Although our data suggest that PRDM16-DT is specifically decreased in the brains of AD patients while remaining unaffected in FTD and schizophrenia patients, we cannot exclude the possibility that PRDM16-DT is affected in other brain diseases. Here, PRDM16 is linked to frontotemporal dementia.